A 66-year-old woman with type C hepatitis had been treated for hepatocellular carcinoma (HCC) with transcatheter arterial embolization and radiofrequency ablation. Liver function worsened gradually to decompensated liver cirrhosis. She had recurrence of HCC and was later admitted to Juntendo University Hospital for living-donor liver transplantation. Although blood glucose was high, she had never been diagnosed with diabetes mellitus. No diabetesrelated complications were detected at that time. We started treatment with multiple insulin injections. There is a unique time called the anhepatic phase during liver transplantation during which the liver does not exist in the body. Recent reports show that it is not necessary to administer glucose for patients with normal glucose tolerance during the anhepatic phase since plasma glucose could be maintained at normoglycemia to hyperglycemia (100-150 mg/dl). In our patient, plasma glucose concentration was rather high during the anhepatic phase without glucose administration. We analyzed the levels of blood glucose, insulin and various other hormones during the anhepatic phase. This could be the first report on glucose homeostasis during the anhepatic phase in a diabetic patient.
THERE is a unique time called the anhepatic phase (the AH) during liver transplantation surgery in which the liver does not exist in the body. The AH begins when the recipient's liver is removed and ends when the circulation through the graft is reestablished by unclamping the portal vein. It has been proposed that the organ that plays the main role in glucose production is the liver. During the AH, glucose homeostasis relies on extrahepatic glucose production, such as renal production. Several studies have discussed glucose homeostasis during the AH in patients with normal glucose tolerance (NGT) [1] [2] [3] [4] , but not in diabetic patients. We present here a diabetic patient and discuss glucose homeostasis during the AH.
Case Report

Before operation
A 66-year-old woman was diagnosed with type C hepatitis in 1996. She was treated for hepatocellular carcinoma (HCC) with transcatheter arterial embolization in 2003 and radiofrequency ablation in 2004. Liver dysfunction worsened gradually to decompensated liver cirrhosis. Furthermore, she developed HCC recurrence in April 2005. She was admitted to Juntendo University Hospital for living-donor liver transplantation in May 2005. While she had never been diagnosed with diabetes mellitus, blood glucose was very high (512 mg/dl, HbA 1c 12.9%) and required multiple insulin injections on admission. She could not remember her blood transfusion history.
She was 158 cm tall and weighed 42.0 kg. Arterial blood pressure was 118/70 mmHg, pulse rate was 78 beats/min and regular, and body temperature was 35.8°C. Physical examination on admission showed anemia, jaundice, massive ascites, and bilateral leg edema. Neurological examination was negative. Diabetic neuropathy and retinopathy were not suspected.
Laboratory data (Table 1) showed liver dysfunction and blood coagulation abnormalities, hypoalbuminemia, pancytopenia, and elevated tumor marker of HCC. Child-Pugh's classification was grade C. Abdominal ultrasonography and computed tomography revealed marked liver atrophy, multiple HCCs, splenomegaly, and massive ascites. One blue esophageal varix was detected by gastro-intestinal fiberscopy. No abnormalities were found on colonoscopy.
Treatment with albumin product and amino acid transfusion resulted in improvement of liver function and ascites to grade B on Child-Pugh's classification. Total daily dose of insulin just before the operation was 28 units (insulin dose before operation: basal dose, 4 units; bolus dose, 24 units).
Her son was the donor and no abnormalities were found in pre-operation examination.
During Operation
A living-donor liver transplantation was performed in August 2005. The operation time was 735 minutes and the AH lasted 50 minutes (365 to 415 minutes from the beginning of the operation). Blood loss was 810 ml. Blood transfusion included 10 units of platelet concentrates (210 gram) and 20 units of fresh frozen plasma (1790 gram). During the AH, 5 units of fresh frozen plasma (450 gram) were administered. Bicarbonated Ringer's solution was mainly used throughout the operation and was the only fluid used during the AH. Plasma glucose (PG) concentration increased gradually during AH, necessitating termination of glucose administration before 170 minutes of the AH. Total amount of administered glucose was 21 gram at that point. Insulin was not administered to avoid hypoglycemia, because we were worried that insulin clearance would disappear during the AH. Methylprednisolone (20 mg/kg) was administered intravenously during the AH to suppress immune response to the graft. Incidentally, the graft was treated with a glucose-free solution consistent with Belzer UW solution (ViaSpan ® , Bristol-Myers Squibb Co.), penicillin, insulin, and dexamethazone before transplantation.
Blood samples were taken every 20 minutes from an arterial catheter in the right radial artery. Figure 1 shows changes of PG, insulin, and C-peptide. Note that PG level ( Fig. 1-A) decreased during the AH; the minimum was rather still above normoglycemia. In fact, PG was high throughout the operation. Insulin and C-peptide ( Fig. 1-B , C) also decreased during the AH. Free fatty acid concentration increased during the AH and decreased immediately after that. Lactate level increased gradually before and decreased during the AH (as analyzed by Lactate Pro LT-1710; Arkray). Ketone body was not detected throughout the operation (as analyzed by Ketometer-N KM-4520; Sanwa kagaku kenkyusyo) (Free fatty acid, lactate and ketone body; data not shown).
Counter regulatory hormones increased during the AH except for growth hormone. During the AH, epinephrine increased from 245 pg/ml to 386 pg/ml and decreased to 112 pg/ml after the AH. Glucagon increased from 530 pg/ml to 2300 pg/ml, and decreased to 1600 pg/ml. Cortisol increased from 29.3 µg/dl to 32.7 µg/dl, and then further increased to 33.7 µg/dl.
Growth hormone decreased from 12.6 ng/ml to 11.1 ng/ml, and then further decreased to 6.63 ng/ml. IGF-1 increased from 42 ng/ml to 47 ng/ml, and then further increased to 69 ng/ml.
After Operation
Total daily dose of insulin was increased to approximately 90 units after the operation, probably due to administration of steroids and/or surgical stress. With reduction of the steroid dose and resumption of donor's liver function, total daily dose of insulin was decreased gradually and was 38 units at discharge without basal insulin. Although tacrolimus is reported to cause β-cell toxicity [1] , there was no relationship between the dose of tacrolimus and total daily dose of insulin in our patient. 
Discussion
The AH is the only time to evaluate extrahepatic glucose production in human being at present. It is interesting to investigate glucose homeostasis during the AH because the liver plays an important role in glucose homeostasis.
Glucose was administered during the AH to prevent hypoglycemia. However, recent studies reported that it is unnecessary to administer glucose to achieve NGT and that PG could be maintained at normoglycemia to hyperglycemia (100-150 mg/dl) [1] [2] [3] [4] . Hypoglycemia during the AH is averted by extrahepatic glucose production. During the AH, several extrahepatic organs can produce glucose at a rate close to that of postabsorptive (overnight fasted) subjects. The kidney is the main organ for extrahepatic glucose production utilizing glutamine, alanine, lactate and glycerol as gluconeogenic precursors, especially from glutamine and alanine [2, 6] , but muscles and gut do not produce glucose [4] .
We experienced a rare case of living-donor liver transplantation with diabetes. In this case, PG was rather high without glucose administration during the AH. While PG increased to hyperglycemia not only in this case with diabetes but also in patients with NGT, extrahepatic glucose production (mainly by the kidney) may not be influenced by PG and insulin level, or feedback pathways from the liver to kidney or other organs may exist. In the normal state, the liver may regulate extrahepatic glucose production.
The difference between our case and previous reports on NGTs is that PG was higher than 200 mg/dl during the AH. We speculated that the glucose produced by extrahepatic organs was not taken up by tissues because of 1) absence of the liver, and 2) increased peripheral insulin resistance. It is probable that the latter is the main factor, because the former is a state similar to NGT.
Previous studies have demonstrated the lack of relationship between hyperglycemia detected during liver transplantation and glucose load associated with transfused blood products [1, 4] .
Hepatic insulin clearance disappears and falls to zero during the AH, because blood flow from the pancreatic vein to portal vein is shut off, and the pancreatic vein flows directly into the main vein. Thus, insulin and C-peptide were expected to increase during the AH, as reported previously [5] . In contrast, both insulin and C-peptide decreased slightly in our case.
Increases in counter regulatory hormones such as epinephrine, cortisol, and glucagon have been reported during the AH [2, 3] , similar to the present case. These hormones might influence hyperglycemia during the AH, though the reports that investigated these hormones during the AH did not elucidate the mechanism of such effect. Other studies suggested that epinephrine and hypoglycemia stimulate renal glucose production [7] [8] [9] . Epinephrine increased during the AH in our case as well. It is also possible that epinephrine-induced renal glucose production is not influenced by PG and insulin level.
More research is needed to assess glucose homeostasis and hormonal changes during the AH. In conclusion, PG was rather high during the AH without glucose administration in diabetic patients.
